High Grade Glioma is the lead indication

Addition BMX-001 to standard treatment of Temozolomide and Radiation Therapy shows increased survival

  • With standard of care, reported median survival is 14-16 months
  • Phase 1 trial with addition of BMX-001 to standard of care shows a median survival of 23.4 months

Reduced side effects of radiation therapy and chemotherapy

Excellent safety/tolerability

Significant unmet need

Phase 2 trial is on-going with potential for Accelerated Approval

Open INDs

Indication

Program

IND 128815

Head and Neck Cancer

Oncology

IND 124640

High-Grade Glioma

Oncology

IND 135918

Anal Cancer

Oncology

IND 139585

Brain Cancer

Oncology

IND 129165

Atopic Dermatitis Plaque Psoriasis

Rosacea

Acne Vulgaris

Dermatology